<prompt> Polysacharide pneumococcal vaccine used in all EXCEPTSickle cell anemiaLess than 2 years of childrenMore than 65 years of manAsplenia  <response>: Less than 2 years of age: 914-Nelson 19th edition 1158-59- H 18th edition; 147-685- Davidson 21st Immunologic responsiveness and efficacy following administration of pneumococcal polysaccharide vaccines is unpredictable in children 2 years of age 914- Nelson 19thed High risk children 2yr of age, such as those with asplenia, sickle cell disease, some types of immune deficiency eg.antibody deficiencies. HIV infections, Cochlear implant CSF leak, DM and chronic lung, heart or kidney disease including nephritic syndrome may benefit also from PPSV23 administered after 2 years of age following priming with the scheduled dose of 13 valent pneumococcal conjugated vaccine PCV-13RECOMMENDED ROUTINE VACCINATION SCHEDULE FOR 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE PCV13 AMONG INFANTS AND CHILDREN WHO HAVE NOT RECEIVED PREVIOUS DOSE OF 7-VALENT VACCINE PCV7 OR PCV13, BY AGE AT FIRST DOSE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES ACIP, USA, 2010AGE AT FIRST DOSE M0PRIMARY PCV13 SERIESPCV13 BOOSTER DOSE2-63 doses1 dose at age 12-15 m07-112 doses1 dose at age 12-15 m012-232 doses-24-59 healthy children1 dose-24-71 children with certain chronic diseases or immunocompromising conditions2 doses-Capsular polysaecharide vaccine Pneumococcal polysaccharide vaccine PPV-23 All person 65 years of age and for those 2- 64 years of age Revaccination 5 years after the first dose is recommended for person 2 years of agePolysaccharide - protein conjugate vaccine PCV - developed especially for infants and young children 